Federal Register / Vol. 62, No. 215 / Thursday, November 6, 1997 / Notices 60095

being considered as well as to make it

more user friendly. Respondents: State,

Local or Tribal Governments; not-forprofit institutions; Total Number of

Respondents: 114 per calendar year;

Number of Responses per Respondent:

One response per request; Average

Burden per Response: 200 hours;

Estimated Annual Burden: 22,800

hours.

Send comments to Douglas F. Mortl,

PSC Reports Clearance Officer, Room

17A08, Parklawn Building, 5600 Fishers

Lane, Rockville, MD 20857. Written

comments should be received within 60

days of this notice.

Dated: October 30, 1997.

Lynnda M. Regan,

Director, Program Support Center.

[FR Doc. 97–29349 Filed 11–5–97; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F-0440]

Cytec Industries, Inc.; Filing of Food

Additive Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Cytec Industries, Inc., has filed a

petition proposing that the food additive

regulations be amended to provide for

the safe use of 1,6-hexanediamine, N,N′-

bis(2,2,6,6-tetramethyl-4-piperidinyl)-,

polymers with morpholine-2,4,6-

trichloro-1,3,5-triazine reaction

products, methylated, as a stabilizer for

olefin polymers intended for use in

contact with food.

FOR FURTHER INFORMATION CONTACT: Vir

D. Anand, Center for Food Safety and

Applied Nutrition (HFS-216), Food and

Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202-418-3081.

SUPPLEMENTARY INFORMATION: Under the

Federal Food, Drug, and Cosmetic Act

(sec. 409(b)(5) (21 U.S.C. 348(b)(5))),

notice is given that a food additive

petition (FAP 8B4562) has been filed by

Cytec Industries, Inc., c/o Keller and

Heckman, 1001 G St. NW., suite 500

West, Washington, DC 20001. The

petition proposes to amend the food

additive regulations in § 178.2010

Antioxidants and/or stabilizers for

polymers (21 CFR 178.2010) to provide

for the safe use of 1,6-hexanediamine,

N,N′-bis(2,2,6,6-tetramethyl-4-

piperidinyl)-, polymers with

morpholine-2,4,6-trichloro-1,3,5-triazine

reaction products, methylated, as a

stabilizer for olefin polymers complying

with 21 CFR 177.1520 intended for use

in contact with food.

The agency has determined under 21

CFR 25.32(i) that this action is of the

type that does not individually or

cumulatively have a significant effect on

the human environment. Therefore,

neither an environmental assessment

nor an environmental impact statement

is required.

Dated: October 16, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval,

Center for Food Safety and Applied Nutrition.

[FR Doc. 97–29347 Filed 11–5–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Peripheral and Central Nervous

System Drugs Advisory Committee

Meeting; Cancellation

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is canceling the

meeting of the Peripheral and Central

Nervous System Drugs Advisory

Committee scheduled for November 18

and 19, 1997. The meeting was

announced in the Federal Register of

October 17, 1997 (62 FR 54118).

FOR FURTHER INFORMATION CONTACT:

Ermona B. McGoodwin or Danyiel

D’Antonio, Center for Drug Evaluation

and Research (HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–5455, or

FDA Advisory Committee Information

Line, 1–800–741–8138 (301–443–0572

in the Washington, DC area), code

12543.

Dated: October 30, 1997.

Michael A. Friedman.

Deputy Commissioner for Operations.

[FR Doc. 97–29348 Filed 11–5–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meetings:

Name of SEP: Phase II Clinical Trails of

New Chemopreventive Agents.

Date: November 18, 1997.

Time: 9:00 a.m. to adjournment.

Place: Double Tree Hotel-Rockville, 1750

Rockville Pike, Rockville, MD 20852.

Contact Person: Wilna Woods, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 622B, 6130 Executive Boulevard, MSC

7405, Bethesda, MD 20892–7405, Telephone:

301/496–7903.

Purpose/Agenda: To review, discuss and

evaluate responses to Request for Proposal.

Name of SEP: Phase I Clinical Studies of

Chemopreventive Agents.

Date: November 29–20, 1997.

Time: November 19–9:00 a.m. to recess;

November 20–9:00 a.m. to adjournment.

Place: Double Tree Hotel-Rockville, 1750

Rockville Pike, Rockville, MD 20852.

Contact Person: Wilna Woods, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 622B, 6130 Executive Boulevard, MSC

7405, Bethesda, MD 20892–7405, Telephone:

301/496–7903.

Purpose/Agenda: To review, discuss and

evaluate responses to Request for Proposal.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

The meetings will be closed in accordance

with the provisions set for in secs. 552b(c)(4)

and 552b(c)(6), Title 5, U.S.C. Proposals and

the discussions could reveal confidential

trade secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

proposals, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: October 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29359 Filed 11–5–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice